Standout Papers
Citation Impact
Citing Papers
Histone demethylase KDM6A directly senses oxygen to control chromatin and cell fate
2019 StandoutScienceNobel
Selective targeting of engineered T cells using orthogonal IL-2 cytokine-receptor complexes
2018 StandoutScienceNobel
Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles
2005 Standout
A target selection of somatic hypermutations is regulated similarly between T and B cells upon activation-induced cytidine deaminase expression
2005 StandoutNobel
C-terminal region of activation-induced cytidine deaminase (AID) is required for efficient class switch recombination and gene conversion
2014 StandoutNobel
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet
2009 Standout
( R )-2-Hydroxyglutarate Is Sufficient to Promote Leukemogenesis and Its Effects Are Reversible
2013 StandoutScienceNobel
Dynamic Single-Cell Network Profiles in Acute Myelogenous Leukemia Are Associated with Patient Response to Standard Induction Therapy
2010
Mutation Analysis of Isocitrate Dehydrogenase in Acute Lymphoblastic Leukemia
2012
Progress and challenges towards targeted delivery of cancer therapeutics
2018 Standout
IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis
2010
Hallmarks of Cancer: The Next Generation
2011 Standout
Platelet factor 4–induced T H 1-T reg polarization suppresses antitumor immunity
2024 StandoutScienceNobel
IDH mutations in primary myelofibrosis predict leukemic transformation and shortened survival: clinical evidence for leukemogenic collaboration with JAK2V617F
2011
Therapy-Related Clonal Hematopoiesis in Patients with Non-hematologic Cancers Is Common and Associated with Adverse Clinical Outcomes
2017
Post-remission therapy for acute myeloid leukemia
2014
Matrices and scaffolds for protein delivery in tissue engineering
2007
A view on drug resistance in cancer
2019 StandoutNature
Acute lymphoblastic leukaemia
2008
Chromosome Aberrations, Gene Mutations and Expression Changes, and Prognosis in Adult Acute Myeloid Leukemia
2006
Cancer-associated IDH mutations: biomarker and therapeutic opportunities
2010
The Potential for Isocitrate Dehydrogenase Mutations to Produce 2-Hydroxyglutarate Depends on Allele Specificity and Subcellular Compartmentalization
2012
Oncogenic kinase signalling
2001 StandoutNature
Differential prognostic effect of IDH1 versus IDH2 mutations in myelodysplastic syndromes: a Mayo Clinic Study of 277 patients
2011
RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia
2011 StandoutNature
A Central Role of Perforin in Cytolysis?
1991
Cytogenetics in acute leukemia
2003
New treatment for acute myelogenous leukemia
2014
IDH mutations in glioma and acute myeloid leukemia
2010
Role of AID in Tumorigenesis
2007 StandoutNobel
Mutations and Treatment Outcome in Cytogenetically Normal Acute Myeloid Leukemia
2008
Cancer Stem Cells: Are We Missing the Target?
2004
IDH mutations in acute myeloid leukemia
2012
Clinical Implications of Novel Mutations in Epigenetic Modifiers in AML
2011
Chemotherapy-resistant human AML stem cells home to and engraft within the bone-marrow endosteal region
2007
What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer
2013 StandoutNobel
Chronic myelogenous leukemia: A review
1996
Inherited Predisposition to Acute Myeloid Leukemia
2014
Targeting multidrug resistance in cancer
2006 Standout
Translational implications of somatic genomics in acute myeloid leukaemia
2014
Use of nanoscale delivery systems to maintain synergistic drug ratiosin vivo
2010
Chemotherapy and the war on cancer
2005 Standout
Stem cell gene expression programs influence clinical outcome in human leukemia
2011
Immunity, Inflammation, and Cancer
2010 Standout
Philadelphia Chromosome–Positive Acute Myeloid Leukemia
2007
Revised guideline on immunophenotyping in acute leukaemias and chronic lymphoproliferative disorders
2002
Tumour heterogeneity and cancer cell plasticity
2013 StandoutNature
Cytotoxicity mediated by T cells and natural killer cells is greatly impaired in perforin-deficient mice
1994 StandoutNature
Taking dendritic cells into medicine
2007 StandoutNatureNobel
Cell-mediated cytotoxicity
1993 StandoutNobel
p53 gene mutations are associated with poor survival in low and low-intermediate risk diffuse large B-cell lymphomas
2002
Genomic Aberrations and Survival in Chronic Lymphocytic Leukemia
2000 Standout
Synergistic Innate and Adaptive Immune Response to Combination Immunotherapy with Anti-Tumor Antigen Antibodies and Extended Serum Half-Life IL-2
2015
Leukaemogenesis: more than mutant genes
2009
Molecular Genetic Pathways as Therapeutic Targets in Acute Myeloid Leukemia
2008
New cancer targets emerging from studies of the Von Hippel‐Lindau tumor suppressor protein
2010 StandoutNobel
Clonal evolution in cancer
2012 StandoutNature
Treatment of Acute Lymphoblastic Leukaemia
2007
Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia in First Complete Remission
2009
The AID Dilemma
2012 StandoutNobel
Liposomal drug delivery systems: From concept to clinical applications
2012 Standout
NF-κB functions as a tumour promoter in inflammation-associated cancer
2004 StandoutNature
Type and location of isocitrate dehydrogenase mutations influence clinical characteristics and disease outcome of acute myeloid leukemia
2012
A common E2F-1 and p73 pathway mediates cell death induced by TCR activation
2000 StandoutNatureNobel
Identification of additional IDH mutations associated with oncometabolite R(−)-2-hydroxyglutarate production
2011
The occurrence and significance of V gene mutations in B cell—Derived human malignancy
2001
CXCR3 ligands in disease and therapy
2014
Angiogenesis as a therapeutic target
2005 StandoutNature
Molecular Diagnosis of the Hematologic Cancers
2003
The cancer genome
2009 StandoutNature
Chronic Lymphocytic Leukemia
2005
Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute–Working Group 1996 guidelines
2008 Standout
Molecular Classification of Cancer: Class Discovery and Class Prediction by Gene Expression Monitoring
1999 StandoutScience
Prognostic impact and targeting of CRM1 in acute myeloid leukemia
2013
Tumour stem cells and drug resistance
2005 Standout
Nanoparticles in the clinic
2016
Accumulation of the FACT complex, as well as histone H3.3, serves as a target marker for somatic hypermutation
2013 StandoutNobel
Nanoparticle Delivery of Cancer Drugs
2011
Photoexpulsion of Surface-Grafted Ruthenium Complexes and Subsequent Release of Cytotoxic Cargos to Cancer Cells from Mesoporous Silica Nanoparticles
2013 StandoutNobel
MLD according to the WHO classification in AML has no correlation with age and no independent prognostic relevance as analyzed in 1766 patients
2007
Activation-induced cytidine deaminase (AID) promotes B cell lymphomagenesis in Emu-cmyc transgenic mice
2007 StandoutNobel
Molecular Genetics of Adult Acute Myeloid Leukemia: Prognostic and Therapeutic Implications
2011
Acute Myeloid Leukemia
2015 Standout
Nanoparticles in the clinic: An update
2019
Decrease in topoisomerase I is responsible for activation-induced cytidine deaminase (AID)-dependent somatic hypermutation
2011 StandoutNobel
The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes
2009 Standout
Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification?
2006
Deregulated expression of the Myc cellular oncogene drives development of mouse “Burkitt-like” lymphomas from naive B cells
2004
Chronic lymphocytic leukemia of Eμ-TCL1 transgenic mice undergoes rapid cell turnover that can be offset by extrinsic CD257 to accelerate disease progression
2009
Patients With t(8;21)(q22;q22) and Acute Myeloid Leukemia Have Superior Failure-Free and Overall Survival When Repetitive Cycles of High-Dose Cytarabine Are Administered
1999
Mutations in epigenetic modifiers in the pathogenesis and therapy of acute myeloid leukemia
2013
Detection and Possible Prognostic Relevance ofp53Gene Mutations in Diffuse Large B-cell Lymphoma. An Analysis of 51 Cases and Review of the Literature
2004
Somatic mutation of bcl-6 genes can occur in the absence of VH mutations in chronic lymphocytic leukemia
2000
Transcriptional silencing of the p73 gene in acute lymphoblastic leukemia and Burkitt's lymphoma is associated with 5' CpG island methylation.
1999
Clinical characterization of acute myeloid leukemia with myelodysplasia-related changes as defined by the 2008 WHO classification system
2009
Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients
2003 StandoutNobel
Subclonal phylogenetic structures in cancer revealed by ultra-deep sequencing
2008
Allogeneic hematopoietic cell transplantation for adults with acute myeloid leukemia: myths, controversies, and unknowns
2010
Antibody therapy for acute myeloid leukaemia
2013
RUNX1Mutations in Acute Myeloid Leukemia: Results From a Comprehensive Genetic and Clinical Analysis From the AML Study Group
2011
How I treat refractory and early relapsed acute myeloid leukemia
2015
The molecular biology of chronic myeloid leukemia
2000
Treatment of the Newly Diagnosed Adult with De Noyo Acute Myeloid Leukemia
1993
T cells expressing an anti–B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma
2016
Single-Cell Mass Cytometry of Differential Immune and Drug Responses Across a Human Hematopoietic Continuum
2011 StandoutScience
Effect of Diagnosis (Refractory Anemia With Excess Blasts, Refractory Anemia With Excess Blasts in Transformation, or Acute Myeloid Leukemia [AML]) on Outcome of AML-Type Chemotherapy
1997
Ongoing In Vivo Immunoglobulin Class Switch DNA Recombination in Chronic Lymphocytic Leukemia B Cells
2002
Chronic lymphocytic leukemia B cells expressing AID display dissociation between class switch recombination and somatic hypermutation
2003
Unmutated Ig VH Genes Are Associated With a More Aggressive Form of Chronic Lymphocytic Leukemia
1999 Standout
Structure of P-Glycoprotein Reveals a Molecular Basis for Poly-Specific Drug Binding
2009 StandoutScience
Survivin is expressed on CD40 stimulation and interfaces proliferation and apoptosis in B-cell chronic lymphocytic leukemia
2001
RNA editing of hepatitis B virus transcripts by activation-induced cytidine deaminase
2013 StandoutNobel
Rapid Induction of Tumor-specific Type 1 T Helper Cells in Metastatic Melanoma Patients by Vaccination with Mature, Cryopreserved, Peptide-loaded Monocyte-derived Dendritic Cells
2002
IDH mutations in Primary Myelofibrosis Predict Leukemic Transformation and Shortened Survival: Clinical Evidence for Leukemogenic Collaboration with JAK2V617F
2011
Rational Design of Bisphosphonate Lipid-like Materials for mRNA Delivery to the Bone Microenvironment
2022 StandoutNobel
Throughput-scalable manufacturing of SARS-CoV-2 mRNA lipid nanoparticle vaccines
2023 StandoutNobel
Chemotherapy triggers HIF-1–dependent glutathione synthesis and copper chelation that induces the breast cancer stem cell phenotype
2015 StandoutNobel
The World Health Organization (WHO) classification of the myeloid neoplasms
2002 Standout
CAR T cell immunotherapy for human cancer
2018 StandoutScience
Synthesis of bioactive protein hydrogels by genetically encoded SpyTag-SpyCatcher chemistry
2014 StandoutNobel
Functional requirements of AID’s higher order structures and their interaction with RNA-binding proteins
2016 StandoutNobel
Somatic mutation of bcl-6 genes can occur in the absence of VH mutations in chronic lymphocytic leukemia
2000
Treatment of the newly diagnosed adult with de novo acute myeloid leukemia.
1993
Works of Jonathan E. Kolitz being referenced
Prognostic Significance of, and Gene and MicroRNA Expression Signatures Associated With, CEBPA Mutations in Cytogenetically Normal Acute Myeloid Leukemia With High-Risk Molecular Features: A Cancer and Leukemia Group B Study
2008
Favorable Prognostic Impact of NPM1 Mutations in Older Patients With Cytogenetically Normal De Novo Acute Myeloid Leukemia and Associated Gene- and MicroRNA-Expression Signatures: A Cancer and Leukemia Group B Study
2009
Pharmacokinetics of recombinant interleukin 2 in humans.
1990
A Phase II study of Bcl-2 antisense (oblimersen sodium) combined with gemtuzumab ozogamicin in older patients with acute myeloid leukemia in first relapse
2006
Remarkably similar antigen receptors among a subset of patients with chronic lymphocytic leukemia
2004
Lineage specific treatment of adult patients with acute lymphoblastic leukemia in first remission with anti‐B4‐blocked ricin or high‐dose cytarabine
2003
Fludarabine Compared with Chlorambucil as Primary Therapy for Chronic Lymphocytic Leukemia
2000
In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells
2005
High dose cytarabine plus gemtuzumab ozogamicin for patients with relapsed or refractory acute myeloid leukemia: Cancer and Leukemia Group B study 19902
2010
MicroRNA Expression in Cytogenetically Normal Acute Myeloid Leukemia
2008
Comparison of Cytogenetic and Molecular Genetic Detection of t(8;21) and inv(16) in a Prospective Series of Adults With De Novo Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study
2001
Overexpression of the ETS-Related Gene, ERG, Predicts a Worse Outcome in Acute Myeloid Leukemia With Normal Karyotype: A Cancer and Leukemia Group B Study
2005
Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720
2002
Dose Escalation Studies of Cytarabine, Daunorubicin, and Etoposide With and Without Multidrug Resistance Modulation With PSC-833 in Untreated Adults With Acute Myeloid Leukemia Younger Than 60 Years: Final Induction Results of Cancer and Leukemia Group B Study 9621
2004
Granulocyte Colony-Stimulating Factor (Filgrastim) Accelerates Granulocyte Recovery After Intensive Postremission Chemotherapy for Acute Myeloid Leukemia With Aziridinyl Benzoquinone and Mitoxantrone: Cancer and Leukemia Group B Study 9022
1997
Prognostic Importance of MN1 Transcript Levels, and Biologic Insights From MN1-Associated Gene and MicroRNA Expression Signatures in Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study
2009
Final results of a phase III randomized trial of CPX-351 versus 7+3 in older patients with newly diagnosed high risk (secondary) AML.
2016
First-In-Man Study of CPX-351: A Liposomal Carrier Containing Cytarabine and Daunorubicin in a Fixed 5:1 Molar Ratio for the Treatment of Relapsed and Refractory Acute Myeloid Leukemia
2011
BAALC expression predicts clinical outcome of de novo acute myeloid leukemia patients with normal cytogenetics: a Cancer and Leukemia Group B Study
2003
Prognostic Factors and Outcome of Core Binding Factor Acute Myeloid Leukemia Patients With t(8;21) Differ From Those of Patients With inv(16): A Cancer and Leukemia Group B Study
2005
Adverse Prognostic Significance of KIT Mutations in Adult Acute Myeloid Leukemia With inv(16) and t(8;21): A Cancer and Leukemia Group B Study
2006
Identification of outcome-correlated cytokine clusters in chronic lymphocytic leukemia
2011
High Expression Levels of the ETS-Related Gene, ERG, Predict Adverse Outcome and Improve Molecular Risk-Based Classification of Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study
2007
Persistence of DNMT 3A R882 mutations during remission does not adversely affect outcomes of patients with acute myeloid leukaemia
2016
Comparison of Clinical and Biologic Significance of WT1 Mutations in Populations of Older (≥60 years[y]) and Younger (<60 y) Adult Patients (Pts) with Cytogenetically Normal (CN) De Novo Acute Myeloid Leukemia (AML): a Cancer and Leukemia Group B (CALGB) Study.
2009
Telomere length and telomerase activity delineate distinctive replicative features of the B-CLL subgroups defined by immunoglobulin V gene mutations
2003
Ig V Gene Mutation Status and CD38 Expression As Novel Prognostic Indicators in Chronic Lymphocytic Leukemia
1999 Standout
Effective asparagine depletion with pegylated asparaginase results in improved outcomes in adult acute lymphoblastic leukemia: Cancer and Leukemia Group B Study 9511
2007
Examples of in vivo isotype class switching in IgM+ chronic lymphocytic leukemia B cells.
1996
BAALC, the human member of a novel mammalian neuroectoderm gene lineage, is implicated in hematopoiesis and acute leukemia
2001
FLT3 D835/I836 mutations are associated with poor disease-free survival and a distinct gene-expression signature among younger adults with de novo cytogenetically normal acute myeloid leukemia lacking FLT3 internal tandem duplications
2007
High BAALC expression associates with other molecular prognostic markers, poor outcome, and a distinct gene-expression signature in cytogenetically normal patients younger than 60 years with acute myeloid leukemia: a Cancer and Leukemia Group B (CALGB) study
2008
Clonal expansion within the CD4+CD57+ and CD8+CD57+ T cell subsets in chronic lymphocytic leukemia.
1997
Distinction of partially purified human natural killer cytotoxic factor from recombinant human tumor necrosis factor and recombinant human lymphotoxin.
1988
Long-term disease-free survivors with cytogenetically normal acute myeloid leukemia and MLL partial tandem duplication: a Cancer and Leukemia Group B study
2007
Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune responses
2000
Isolated trisomy of chromosomes 8, 11, 13 and 21 is an adverse prognostic factor in adults with de novo acute myeloid leukemia: Results from Cancer and Leukemia Group B 8461
2002
Abnormal Cytogenetics at Date of Morphologic Complete Remission Predicts Short Overall and Disease-Free Survival, and Higher Relapse Rate in Adult Acute Myeloid Leukemia: Results From Cancer and Leukemia Group B Study 8461
2004
Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia
1991
Role of colony-stimulating factors in bone marrow transplantation.
1992
Phase II, multicenter, randomized trial of CPX‐351 (cytarabine:daunorubicin) liposome injection versus intensive salvage therapy in adults with first relapse AML
2014
IDH1 and IDH2 Gene Mutations Identify Novel Molecular Subsets Within De Novo Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study
2010
Outcome of Induction and Postremission Therapy in Younger Adults With Acute Myeloid Leukemia With Normal Karyotype: A Cancer and Leukemia Group B Study
2004
A Systematic Search Into The Role Of IGHV Gene Replacement In Shaping The Immunoglobulin Repertoire Of Chronic Lymphocytic Leukemia
2013
Wilms’ Tumor 1 Gene Mutations Independently Predict Poor Outcome in Adults With Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study
2008
Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia
1991
Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AML
2014
Phase IIb Randomized Study of CPX-351 Vs. Conventional Cytarabine + Daunorubicin in Newly Diagnosed AML Patients Aged 60-75: Safety Report.
2009
Correlation Between Mutation in P53, p53 Expression, Cytogenetics, Histologic Type, and Survival in Patients With B-Cell Non-Hodgkin's Lymphoma
1997
Multiple Distinct Sets of Stereotyped Antigen Receptors Indicate a Role for Antigen in Promoting Chronic Lymphocytic Leukemia
2004